Biocryst Pharmaceuticals (BCRX) EBT Margin Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) EBT Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -1,585.00 |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -177.00 |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -27.00 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -356.00 |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 436.00 |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -629.00 |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 208.00 |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn | 3,244.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,244.00 |
| Mar 31, 2026 | -46,136.00 |
| Dec 31, 2025 | 3.51 Mn |
| Sep 30, 2025 | 1,909.00 |
| Jun 30, 2025 | 1,541.00 |
| Mar 31, 2025 | 3,827.00 |
| Dec 31, 2024 | 4,786.00 |
| Sep 30, 2024 | 2,981.00 |
| Jun 30, 2024 | 7,898.00 |
| Mar 31, 2024 | 3,882.00 |
| Dec 31, 2023 | 2,222.00 |
| Sep 30, 2023 | 1,277.00 |
| Jun 30, 2023 | -191.00 |
| Mar 31, 2023 | 7,149.00 |
| Dec 31, 2022 | -5,692.00 |
| Sep 30, 2022 | 8,937.00 |
| Jun 30, 2022 | -204.00 |
| Mar 31, 2022 | 18,923.00 |
| Dec 31, 2021 | 163,396.00 |
| Sep 30, 2021 | 61,210.00 |